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Quantitative Echocardiographic Determinants
of Clinical Outcome in Asymptomatic Patients
With Aortic Regurgitation
A Prospective Study
Delphine Detaint, MD, David Messika-Zeitoun, MD, Joseph Maalouf, MD,
Christophe Tribouilloy, MD, Douglas W. Mahoney, MS, A. Jamil Tajik, MD, FACC,
Maurice Enriquez-Sarano, MD, FACC
Rochester, Minnesota
O B J E C T I V E S The purpose of this study was to deﬁne the link between aortic regurgitation (AR)
quantitation and clinical outcome in asymptomatic patients with AR.
B A C KG ROUND Quantitative American Society of Echocardiography (QASE) thresholds are recom-
mended for AR assessment, but impact on clinical outcome is unknown.
METHOD S We prospectively enrolled (1991 to 2003) 251 asymptomatic patients (age 60  17
years) with isolated AR and ejection fraction 50% with quantiﬁed AR and left ventricular (LV) volumes
using Doppler-echocardiography.
R E S U L T S Survival under medical management was independently determined by baseline regurgitant
volume (RVol) (adjusted hazard ratio [HR] 1.22 [95% conﬁdence interval (CI) 1.08 to 1.35] per 10 ml/beat, p
 0.002) and effective regurgitant oriﬁce (ERO) (adjusted HR 1.52 [95% CI 1.19 to 1.91] per 10 mm2, p 
0.002), which superseded traditional AR grading. Patients with QASE-severe AR (RVol 60 ml/beat or ERO
30 mm2) versus QASE-mild AR (RVol30 ml and ERO10 mm2) had lower survival (10 years: 69 9% vs.
92 4%, p 0.05) independently of all clinical characteristics (adjusted HR 4.1 [95% CI 1.4 to 14.1], p 0.01)
and lower survival free of surgery for AR (10 years: 20  5% vs. 92  4%, p  0.001, adjusted HR 12.9 [95%
CI 5.4 to 38.5]). Cardiac events were considerably more frequent with QASE-severe versus -moderate or -mild
AR (10 years: 63  8% vs. 34  6% and 21  8%, p  0.0001). Independent determinants of cardiac events
were quantitative AR grading (QASE-severe adjusted HR 5.2 [95% CI 2.2 to 14.8], p  0.001; QASE-moderate
adjusted HR 2.4 [95% CI 1.06 to 6.6], p 0.035), which superseded traditional AR assessment (p 0.001) and
LV end-systolic volume index (ESVI) (adjusted HR 1.09 [95% CI 1.03 to 1.14 per 10 ml/m2], p  0.002), which
superseded LV M-mode diameters. In QASE-severe AR, patients with ESVI45 versus45 ml/m2 had higher
cardiac event rates (10 years: 87  8% vs. 40  10%, p  0.001). Cardiac surgery for AR reduced cardiac
events in patients with QASE-severe AR (adjusted HR 0.23 [95% CI 0.09 to 0.57], p  0.002).
CONC L U S I O N S Echocardiographic quantitation of AR severity and ESVI provides independent
and superior predictors of clinical outcome in asymptomatic patients with AR and ejection fraction
50% and should be widely clinically applied. Patients with QASE-severe AR and ESVI45 ml/m2 should
be carefully considered for cardiac surgery, which reduces cardiac events risk. (J Am Coll Cardiol Img
2008;1:1–11) © 2008 by the American College of Cardiology Foundation
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2n patients with aortic regurgitation (AR), symp-
toms of heart failure (1–3) and reduced ejection
fraction (EF) (3–5) are major determinants of
outcome definitely indicating aortic valve replace-
ent (6). However, in asymptomatic patients with
reserved EF, predictors of survival after diagnosis
re uncertain (7–9). These uncertainties stem from
ow mortality rates in young and healthy popula-
ions enrolled in natural history studies (7–9),
ontrasting with those observed in clinical practice
3), or from lack of a specific measure of AR severity
10). Hence, high-risk groups among asymptomatic
atients with AR and left ventricular (LV) EF
50% are poorly defined, so that surgical indica-
ions remain unclear and are rarely applicable on the
asis of current clinical guidelines (6).
See page 12
However, recent guidelines endorsed by American
and European cardiology societies noted
limitations of standard qualitative AR as-
sessment (11,12) and LV assessment by
diameters (13,14) and emphasized impor-
tance of quantitative measurements. These
guidelines provided quantitative American
Society of Echocardiography (QASE)
thresholds for AR grading (10) and recom-
mended LV volume quantitation (15) for
improved LV assessment (16,17). However,
the role of quantitative echocardiographic
measurements in predicting outcome of
asymptomatic patients with AR is unknown.
For this purpose, we prospectively enrolled
symptomatic patients with AR and EF 50% in
hom we quantified AR and LV volumes at diagnosis
ith Doppler echocardiography to analyze outcome
ccording to quantitative AR grading. We hypothe-
ized that quantitative echocardiographic measure-
ents (specifically QASE AR grading) independently
redict clinical outcome and define high-risk patient
ubsets.
E T H O D S
tudy design. The study design was approved by
nstitutional review board to: 1) prospectively enroll
atients with AR in whom the authors quantified
egurgitation and LV volumes at diagnosis; 2) have
atients forming this cohort clinically managed by
heir independent physicians (with all information
vailable); 3) complete all off-line echocardio-
r
anraphic measurements in a secure database; and Then 4) record all deaths, cardiac events, and aortic
alve surgeries during follow-up by their indepen-
ent physicians. This design was chosen to mini-
ize investigators’ interference with patients’ man-
gement, limit healthy participant bias by not
equiring mandatory follow-up appointments (3,7),
nd ensure baseline data completion before clinical
vents’ ascertainment. The study was designed in
990 to 1991 (18), enrolled the first patient in 1991,
nd was continued with consecutive enrollment of
ll eligible patients examined by the authors. The
merican Society of Echocardiography guidelines
10), in which we (M.E.S) participated actively,
ere prepared later, but are in complete agreement
ith the present study’s approaches.
tudy population. After oral consent, patients were
onsecutively and prospectively enrolled by investi-
ators between 1991 and 2003 if they were asymp-
omatic and their AR was: 1) at least mild by
tandard color-flow imaging (19); 2) pure (no ste-
osis) and isolated (no other valve disease); and 3)
valuated with quantitative echocardiography for
R degree and LV volumes. Exclusion criteria
ere: 1) symptoms at diagnosis (7); 2) aortic dis-
ection or ongoing endocarditis; 3) functional AR
ue to hypertension; 4) associated aortic systolic
radient 20 mm Hg; 5) concomitant mitral valve,
ongenital (other than bicuspid valve), or pericardial
isease; 6) previous valve repair or replacement; and
) EF 50% (6,20). No exclusions were based on
ender, age, cardiac rhythm, or treatment received.
linical evaluation and management. Patients were
valuated and treated by their independent physi-
ians, who were provided with all results of Doppler
chocardiography. Diagnosis of congestive heart
ailure was based on Framingham criteria (21).
trial fibrillation was diagnosed by electrocardio-
ram. Comorbid conditions were evaluated with
alidated Charlson index (22). Follow-up was col-
ected in 2006 and 2007 after closure of enrollment
nd of all baseline data collection procedures.
auses of events and deaths were established by
eview of medical, coroner, and autopsy records or
eath certificates.
oppler echocardiography. AR ASSESSMENT. Com-
rehensive Doppler echocardiography was per-
ormed (23). The AR was prospectively assessed
uantitatively and qualitatively. The AR quantita-
ion used 3 validated methods, eventually averaged
o calculate both regurgitant volume (RVol) and
ffective regurgitant orifice (ERO) area (85% of
atients had 2 of 3 methods of quantification).B B R E V I A T I O N S
N D A C R O N YM S
R aortic regurgitation
F ejection fraction
RO effective regurgitant
rifice
SVI end-systolic volume
ndex
V left ventricle/ventricula
ASE quantitative Americ
ociety of Echocardiographyhese methods were quantitative Doppler based on
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3ortic and mitral stroke volume measurement
18,24), quantitative 2-dimensional echocardiogra-
hy on the basis of LV and mitral stroke volume
15,24), and proximal isovelocity surface area
ethod analyzing proximal flow convergence (25).
he QASE guidelines regarding AR grading (10)
efine regurgitant volume 30 and 60 ml/beat
nd ERO 10 and 30 mm2 as thresholds for,
espectively, mild and severe regurgitation. Thus,
ASE-severe AR was defined as regurgitant vol-
me 60 ml/beat or ERO 30 mm2, QASE-mild
R required both regurgitant volume 30 ml/beat
nd ERO10 mm2, and QASE-moderate AR was
arger than mild (regurgitant volume 30 ml/beat
r ERO 10mm2), but not reaching QASE-severe
riteria. The AR qualitative assessment also pro-
pectively graded AR in 4 grades and measured
et-width to LV outflow tract-width ratio (19) by
olor flow imaging measured from parasternal long-
xis views (10).
V ASSESSMENT. The LV end-diastolic and end-
ystolic volume indexes (ESVIs) and EF with
impson disk method and LV mass were measured
s recommended by the American Society of Echo-
ardiography (15). The LV diameters by M-mode
chocardiography were measured as absolute values
nd normalized to body surface area.
tatistical analysis. Data are presented as mean 
D or percent. Group comparisons used analysis of
ariance or the chi-square test, as appropriate. The
utcome end points were survival, survival free of
R surgery, and cardiac events (defined as cardiac
eath, congestive heart failure, or new episode of
trial fibrillation) under medical management. The
ntire follow-up after diagnosis under medical and
urgical management was used to assess the impact
f surgery on outcome with a time-dependent term
n Cox proportional hazard models. Event rates
ith Kaplan-Meier method were expressed as esti-
ated  SE and compared with the log-rank test,
nd linearized rates of first events were estimated.
ime to events was analyzed by Cox proportional
azard with calculation of unadjusted and adjusted
isk ratios. Adjustment in multivariable models
sed age, gender, comorbidity score, and EF in
odels not using ESVI. Comparisons of outcome
redictors (quantitative vs. traditional) used the
oncordance index (26); p  0.05 was significant.
E S U L T S
aseline characteristics. The 251 patients enrolled in
he cohort were followed for a total of 8.0  3.8 Sears (5 years in 188 patients, and10 years in 82
atients; complete up to death or 2006 in 97%). All
ad organic aortic valve disease—due to degenera-
ive disease (with valve thickening, annular enlarge-
ent, and central defect) in 140 patients, bicuspid
alve in 60 patients, dystrophic disease (with thin
eaflet, annular enlargement, with or without valve
rolapse) in 19 patients, rheumatic disease in 6
atients, chronic endocarditic lesions in 6 patients,
nd miscellaneous causes in 20 patients. Baseline
haracteristics are presented in Table 1. Regurgitant
olume and orifice widely ranged from 7 to 212
l/beat and from 3 to 100 mm2, respectively.
roups displayed by QASE grade (10) in Table 1
nvolve 18% QASE-mild, 43% QASE-moderate,
nd 37% QASE-severe. As usually noted (7,9,27),
evere AR showed male predominance, a trend for
ounger age, lower diastolic blood pressure, and
arger LV volume and mass. Jet-width ratio grading
as mild (25%) in 18%, moderate (25% to 64%)
n 74%, and severe (65%) in 8% of patients.
asodilator therapy 6 months during medical
ollow-up included angiotensin-converting enzyme
nhibitors in 100, calcium-channel blockers in 51,
nd angiotensin-receptor blockers in 31 patients.
urvival and cardiac surgery after diagnosis. During
ollow-up, 33 deaths occurred under conservative
anagement with survival 93  2% at 5 years and
8  4% at 10 years. Cardiac surgery was per-
ormed in 81 patients: 1 for aortic dissection and 80
or AR. Indications for surgery for AR were occur-
ence of symptoms in 38, LV dysfunction or en-
argement in 17, aortic aneurysm in 11, infective
ndocarditis in 3, and physician and/or patient
reference in 11 patients. The 10-year rate of
urgery for AR was 36  4%. Thus, for the
ombined end point of survival and freedom from
urgery for AR, 113 events (33 deaths, 80 surgeries)
ccurred with a rate of 50  4% at 10 years.
Univariately (or after adjustment) qualitative as-
essment of AR in 4 grades, with jet-width ratio as
continuous or categorical variable, showed no
ignificant association to survival (all p  0.15).
onversely, quantitative AR measurements were
ssociated with survival after diagnosis univariately
RVol adjusted hazard ratio [HR] 1.17 [95% con-
dence interval (CI) 1.05 to 1.30]/10 ml, p  0.01;
RO adjusted HR 1.50 [95% CI 1.16 to 1.86]/10
m2, p  0.01) and in multivariable analysis as
ontinuous variables or as QASE-severe AR grad-
ng (adjusted HR 4.1 [95% CI 1.4 to 14.1] com-
ared with QASE-mild AR, p  0.01) (Table 2).
tratified by QASE-AR grading, survival under
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4onservative management was lower in QASE-
evere versus QASE-moderate and QASE-mild
R (at 5 years, 82 6% vs. 95 2% and 98 2%,
espectively, p  0.05) (Fig. 1). Adjusting addi-
ionally for vasodilator therapy use, QASE-severe
R remained independently associated with
igher mortality (adjusted HR 6.7 [95% CI 2.2 to
3.2], p  0.02). The QASE-moderate com-
ared with QASE-mild grading showed a trend
or higher mortality (adjusted HR 2.1 [95% CI
.8 to 6.7], p  0.13). The LV end-systolic
iameter (absolute or normalized to body surface
rea) was univariately associated with survival
Table 1. Baseline Characteristics of Asymptomatic Patients Acco
AR Quantitative Classiﬁcation
Overall
(n  251)
Clinical characteristics
Age, yrs 60 17
Male gender, n (%) 167 (67)
Atrial ﬁbrillation, n (%) 11 (4)
Hypertension history, n (%) 123 (49)
Diabetes, n (%) 13 (5)
Charlson comorbidity index, arbitrary units 1.9 2.4
Systolic blood pressure, mm Hg 139 22
Diastolic blood pressure, mm Hg 71 12
Left ventricular characteristics
Ejection fraction, % 68 9
End-systolic diameter index, mm/m2 18 3
End-diastolic volume index, ml/m2 105 25
End-systolic volume index, ml/m2 34 16
Left ventricular mass, g 248 76
AR characteristics
Jet to outﬂow tract width ratio, % 39 14
Regurgitant volume, ml/beat 55 21
ERO, mm2 24 12
*Quantitative American Society of Echocardiography (QASE)-severe aortic regurgit
mm2; QASE-mild AR: regurgitant volume30ml/beat and ERO10mm2; and QASE
but not reaching QASE-severe criteria.
f Survival Free of Surgery for AR and of Cardiac Events With Qu
Threshold
O
Survival*
(n  33)
Hazard Ratio p Value
Compared with QASE-mild‡ 4.1 (1.4–14.1) 0.01
Per 10-ml/beat increment 1.22 (1.08–1.35) 0.002
Per 10-mm2 increment 1.52 (1.19–1.91) 0.002
Compared with 45 ml/m2 — —
ath, congestive heart failure, or new episode of atrial ﬁbrillation. *Hazard ratios ar
tative classiﬁcation, ejection fraction, and comorbidity index. †Hazard ratios are p
ve classiﬁcation, end-systolic volume index (ESVI), and comorbidity index. ‡QASE-s
10 mm2.
1.both p  0.04), and ESVI showed a trend of
ssociation (p  0.12), but both were no longer
ignificant after adjustment for quantitative AR
ssessment (all p  0.30).
In QASE-severe versus QASE-moderate and
ASE-mild AR, surgery for AR was more often
erformed (at 10 years, 72  6% vs. 24  5% and
s. 0%, respectively, p  0.0001), so that the rate of
urvival free of surgery for AR was lower in QASE-
evere AR (at 10 years, 20  5% vs. 57  6% and
2  4%, respectively, p  0.0001; adjusted risk
atio 12.9 [95% CI 5.4 to 38.5] for QASE-severe
R and 4.0 [95% CI 1.7 to 11.8] for QASE-
g to Quantitative AR Grading
E-Mild*
 51)
QASE-Moderate*
(n  107)
QASE-Severe*
(n  93)
p
Value
2 15 62 18 58 18 0.16
2 (43) 67 (63) 78 (84) 0.001
1 (2) 6 (6) 4 (4) 0.58
0 (58) 54 (51) 39 (42) 0.20
1 (2) 5 (5) 7 (8) 0.38
3 1.8 2.2 2.5 1.8 2.4 0.05
0 24 138 20 140 24 0.90
7 14 74 10 64 13 0.001
1 9 68 9 67 9 0.05
7 3 18 3 20 4 0.001
3 15 95 18 133 35 0.001
2 9 31 12 45 22 0.001
7 57 231 72 300 89 0.001
7 12 35 13 49 15 0.001
7 5 41 12 92 32 0.001
7 2 18 6 41 18 0.001
(AR): regurgitant volume 60 ml/beat or effective regurgitant oriﬁce (ERO) 30
erate AR: regurgitationmild (regurgitant volume30ml/beat or ERO10mm2)
iﬁed Degree of AR and ESVI
me Under Medical Management
Survival Free of AVR†
(n  113)
Cardiac Events†
(n  67)
Hazard Ratio p Value Hazard Ratio p Value
2.9 (5.4–38.5) 0.001 5.2 (2.2–14.8) 0.001
.22 (1.16–1.28) 0.001 1.11 (1.05–1.17) 0.001
.42 (1.28–1.57) 0.001 1.17 (1.04–1.30) 0.01
1.8 (1.2–2.7) 0.01 2.4 (1.3–4.3) 0.005
esented with their 95% conﬁdence intervals in parentheses and were adjusted
nted with their 95% conﬁdence interval in parentheses and were adjusted for
e AR: regurgitant volume (RVol) 30 ml/beat or ERO 20 mm2; QASE-mild AR:rdin
QAS
(n
6
2
3
1.
14
7
7
1
7
2
18
2
1
ation
-modTable 2. Association o ant
utco
QASE-severe AR‡ 1
RVol 1
ERO 1
ESVI 45 ml/m2
Cardiac events: cardiac de e pr
for age, gender, AR quanti rese
age, gender, AR quantitati ever
RVol 30 ml/beat and ERO
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5oderate AR vs. QASE-mild AR, both p 0.001)
Fig. 2, Table 2). In patients with QASE-severe
R, linearized yearly mortality rates were markedly
ower after AR surgery (1.7% [95% CI 0.8 to 3.1])
han under conservative management (3.4% [95%
I 1.9 to 5.6]), but the time-dependent mortality
100
50
60
70
80
90
0 1 2
p=0.05
QASE–mild AR
QASE–moderate AR
QASE–severe AR
3 4
Su
rv
iv
al
, %
Figure 1. Survival Under Conservative Management After Diagn
Patients are stratiﬁed according to quantitative American Society of
QASE-severe AR is deﬁned as regurgitant volume 60 ml/beat or e
AR as regurgitant volume 30 ml/beat and ERO 10 mm2 (brown
mild (regurgitant volume 30 ml/beat or ERO 10 mm2), but not
are indicated. Note the lower survival with QASE-severe AR, wherea
5 years after diagnosis, with higher mortality thereafter.
100
0
20
40
60
80
0 1 2
p<0.001
3 4
Su
rv
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al
 fr
ee
 o
f A
VR
, %
QASE–mild AR
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QASE–severe AR
Figure 2. Composite End Point of Survival Free of Surgery for A
Patients are stratiﬁed according to QASE AR grading. The QASE-sev
mm2 (yellow line). The QASE-mild AR as regurgitant volume 30 m
ted orange line) as larger than mild (regurgitant volume 30 ml/b
and 10-year rates of the end point  SE are indicated. Note the wi
 aortic valve replacement; other abbreviations as in Figure 1.eduction did not reach statistical significance (risk
atio 0.64, p  0.38).
ardiac events. Under conservative management, 67
atients incurred cardiac events (cardiac death, con-
estive heart failure, or new atrial fibrillation) with 5-
nd 10-year rates of 27  3% and 39  4%,
8±2
5±2
2±6
92±4
75±6
69±9
5 6 7 8 9 10
ars
of Asymptomatic Aortic Regurgitation
ocardiography (QASE) aortic regurgitation (AR) grading. The
ive regurgitant oriﬁce (ERO) 30 mm2 (yellow line), QASE-mild
), and QASE-moderate AR (dotted orange line) as larger than
hing QASE-severe criteria. The 5- and 10-year survival rates  SE
SE-moderate AR displays survival similar to QASE-mild AR up to
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fter Diagnosis of Asymptomatic AR
AR is deﬁned as regurgitant volume 60 ml/beat or ERO 30
at and ERO 10 mm2 (brown line), and QASE-moderate AR (dot-
or ERO 10 mm2), but not reaching QASE-severe criteria. The 5-
ifference in outcome according to QASE grading at baseline. AVR9
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6espectively. All measures of AR severity, traditional
qualitative 4-grade classification, jet-width ratio con-
inuous or categorical) or quantitative (RVol, ERO),
ere univariately predictive of cardiac events (all p 
.01). However, in models with quantitative AR
rading, traditional AR assessments were no longer
ignificant in predicting cardiac events (all p  0.23).
omparison of outcome prediction involving tradi-
ional AR assessment demonstrated superiority of
ASE-grading for predicting cardiac events (all p 
.001). The RVol and ERO remained predictive of
ardiac events after adjustment in multivariable anal-
sis (Table 2). Stratified by QASE grading, cardiac
vent rates were considerably different (Fig. 3). In
ultivariable analysis (Table 2) adjusted for age,
ender, comorbidity index, and LV ESVI, QASE-
evere AR (adjusted risk ratio 5.2 [95% CI 2.2 to 14.8]
 0.001 vs. QASE-mid AR) and QASE-moderate
R (adjusted risk ratio 2.4 [95% CI 1.06 to 6.6], p
.035 vs. QASE-mild AR) were independently pre-
ictive of cardiac events, even after adjusting for
asodilator use.
All measures of LV end-systolic enlargement, tra-
itional (LV diameter absolute or body surface area
ormalized) or volumetric (ESVI), were univariately
redictive of cardiac events (all p 0.01). However, in
odels with ESVI, traditional measures lost signifi-
ance in predicting cardiac events (both p  0.09).
omparison of outcome prediction involving LV
0
20
10
30
50
40
60
70
80
0 1 2
p<0.0001
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Figure 3. Cardiac Events (Cardiac Death, Congestive Heart Failu
After Diagnosis of Asymptomatic AR
Patients are stratiﬁed according to QASE AR grading. The QASE-sev
mm2 (yellow line), QASE-mild AR as regurgitant volume 30 ml/be
orange line) as larger than mild (regurgitant volume 30 ml/beat
10-year event rates  SE are indicated. Note the progressive increa
tions as in Figure 1.nd-systolic diameter (absolute or body surface area Hormalized) demonstrated superiority of ESVI for
redicting cardiac events (both p  0.002). Baseline
SVI was predictive of cardiac events univariately
adjusted HR 1.09 [95% CI 1.03 to 1.14]/10 ml/m2,
 0.002) and in multivariable analysis (adjusted HR
.23 [95% CI 1.03 to 1.46]/10 ml/m2 or 2.4 [95% CI
.3 to 4.3] for ESVI45 ml/m2) (Table 2). Stratified
y ESVI categories (45, 45 ml/m2), 10-year car-
iac event rates were considerably different overall (31
5% vs. 74  8%, p  0.001) with progressively
ncreasing rates in combination with stratification
sing QASE AR grading (Fig. 4).
Ten-year rates of atrial fibrillation were 14  7%,
4  4%, and 19  7% in QASE-mild, QASE-
oderate, and QASE-severe AR, respectively (p 
.02). If patients with atrial fibrillation as the only
ardiac event are excluded, 61 patients had cardiac
vents (cardiac death or heart failure), with 10-year
ates of 18  8%, 29  5%, and 65  8% in
ASE-mild, QASE-moderate, and QASE-severe
R, respectively (p  0.001). These events were
redicted independently by QASE-severe AR (ad-
usted HR 5.9 [95% CI 2.3 to 18.3], p  0.001) and
SVI 45 ml/m2 (adjusted HR 2.2 [95% CI 1.2 to
.9], p  0.01), with borderline effect of QASE-
oderate AR (adjusted HR 2.3 [95% CI 0.95 to 7.0],
 0.065). Of note, ESVI 45 ml/m2 is similarly
redictive of atrial fibrillation (adjusted HR 2.9 [95%
I 1.6 to 5.1], p  0.02) and heart failure (adjusted
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7The effect of age on outcome was analyzed by
tratifying patients age 50 and 50 years at
iagnosis (Fig. 5). Whereas mortality was minimal
elow age 50 years irrespective of AR severity,
ASE grading was predictive of mortality after age
0 years (Figs. 5A and 5C). Only 9 patients
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8With the entire follow-up in models with time-
ependent surgery for AR, patients with QASE-
oderate AR showed no significant reduction of
ardiac events after surgery (p  0.92). Conversely,
or QASE-severe AR, surgery for AR was associ-
ted with marked reduction of cardiac events (lin-
arized yearly rates 11.2% [95% CI 7.9 to 15.3]
nder medical management decreasing to 2.3%
95% CI 0.9 to 5.0] after surgery, adjusted risk
atio 0.23 [95% CI 0.09 to 0.57], p  0.002).
lso in patients with ESVI 45 ml/m2, surgery
or AR was associated with marked reduction of
ardiac events (linearized yearly rates 14.9% [95%
I 10.2 to 21.0] under medical management
ecreasing to 2.9% [95% CI 1.3 to 6.0] after
urgery, adjusted risk ratio 0.22 [95% CI 0.08 to
.62], p  0.004). If patients with atrial fibrilla-
ion as the only cardiac event are excluded,
urgery for AR markedly lowered the event rate
0.16 [95% CI 0.05 to 0.47], p  0.01).
I S C U S S I O N
he present prospective cohort demonstrates the im-
act of quantitative echocardiography on the clinical
utcome of asymptomatic patients with AR and EF
50%. The RVol and ERO are powerful indepen-
ent predictors of outcome, and patients with QASE-
evere AR (RVol 60 ml/beat or ERO 30 mm2)
ncur excess mortality, cardiac events, and lower sur-
ival free of surgery for AR. Additionally, baseline
SVI 45 ml/m2 independently predicts cardiac
vents. These quantitative measures supersede predic-
ive power of traditional variables (jet assessment and
V diameters), underscoring their importance to clin-
cal decisions. Patients at high risk of cardiac events
isplay a marked reduction of risk after cardiac surgery
or AR (risk almost 5 times lower) so that surgery
hould be considered in patients with QASE-severe
R and ESVI 45 ml/m2.
ationale of the study. Patients with AR and symp-
oms or reduced ventricular function are at higher risk
f cardiovascular death (6). In previous smaller pro-
pective studies (7–9), defining high-risk subsets
mong asymptomatic patients with preserved LVEF
as challenging. Indeed, these series observed only a
ew deaths (average mortality 0.4%/year) (7–9), con-
rasting with clinical practice in which patients are
lder (closer to 60) and mortality of asymptomatic
atients with AR is higher (2.8%/year) (3), close to
ur present series. Thus, clinical guidelines are based
n data involving low mortality and cardiac events and
n inconsistent LV markers of clinical outcome (6). aecommendation of LV diameters, particularly end-
ystolic diameter 55 mm, for class II indications of
urgery is poorly substantiated (6). In our study, only
(1.2%) had such diameters and 95% had both LV
nd-diastolic diameter 70 mm and end-systolic
iameter 50 mm, which represents a contra-
ndication (class III indication) for surgery by clinical
uidelines (6). Conversely, 44 (17.5%) of our patients
ad both QASE-severe AR and ESVI 45 ml/m2
nd were at high risk. Therefore, traditional LV
ndexes used in AR are quite insensitive. Emerging
linical tools by quantitative echocardiography, mea-
uring absolute AR-degree (RVol or ERO) and total
V consequences of AR (LV volumes) raised new
opes. These tools were developed in physiologic
tudies (18,24,28), codified by guidelines of the Amer-
can Society of Echocardiography (10,15), and en-
orsed by major American and European cardiac
ocieties, but their impact on clinical outcome
as unknown. In view of insensitivity and prog-
ostic inferiority of traditional tools (LV diame-
ers) for detecting high-risk patients (6), the
resent data are essential in managing asymptom-
tic patients with AR and preserved EF, among
hich high-risk subsets can now be identified and
ggressively managed.
uantitation of AR. The link between AR degree
nd outcome might seem intuitive, but reports of
severe” AR with very low mortality (7,8,29) cast
oubts on such a link, which was never analyzed,
robably because traditional AR assessment has
erious limitations (11,12). Quantitative methods
10) provided encouraging risk stratification in
ther valve regurgitations (30). Ancillary questions
egarding potential superiority of quantitative as-
essment and specific thresholds proposed by
ASE grading (18,24) required outcome data. The
resent study fills these gaps of knowledge and
hows that QASE AR grading strongly predicts
utcome in asymptomatic patients with EF 50%,
s more sensitive, and supersedes traditional mea-
ures of AR severity, providing essential support for
uantitative assessment. A QASE-severe AR de-
nes patients at notable risk of mortality, cardiac
vents, and with lower survival free of surgery for
R, genuinely justifying the severe label. Hence, for
atients in whom surgery is not indicated by clinical
uidelines (6), quantitative echocardiography
dentifies those at high risk of poor outcome
nder medical management and improved out-
ome with surgery and is particularly important
nd relevant.
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9We averaged 3 methods of AR quantitation for
implicity of presentation. Methods correlate with r
0.90, and all predict cardiac events similarly, so
hat in clinical practice measuring all methods is not
lways indispensable to optimize feasibility. In mi-
ral regurgitation, ERO carries the most predictive
ower (30), but in AR, ERO measuring lesion
everity and RVol measuring volume overload (24)
re equipotent for outcome prediction and comple-
entary.
uantitation of LV volumes. Patients with LV dys-
unction complicating AR incur high mortality (3),
ven after surgery (5). However, in patients with
normal” EF, LV dysfunction development is rare
7,29). Disagreement on ventricular indexes pre-
icting outcome (3,7,8,29) reflects LV diameter’s
hortcomings as a measure of LV remodeling (13).
he ESVI was assessed in a small angiographic
eries examining only post-operative outcome
16,17). Our study provides new information with
chocardiographic ESVI predicting clinical out-
ome and superseding LV diameters. Despite “pre-
erved” EF, higher ESVI (45 ml/m2) indepen-
ently predicts more cardiac events within each AR
rade. This result reconciles previous discordant
ata (3,7,16,17,29,31,32) and, by normalizing to
ody size, is equally applicable to men and women,
voiding gender-bias from non-normalized LV di-
ensions (14). Thus, quantitative echocardiogra-
hy provides comprehensive determinants of out-
ome and is essential for clinical management of
symptomatic AR.
linical implications. Quantitative echocardiography
efines prognosis in patients with AR and should
e encouraged and generalized (10,15). The RVol
nd ERO should be measured at diagnosis; patients
eaching thresholds (60 ml/beat, 30 mm2, re-
pectively) have severe AR and, with ESVI 45
l/m2, are at risk for poor outcome. Considerable
ost-operative outcome improvement is a strong
ncentive to consider surgery. Patients with either
but not both) quantitative criteria (QASE-severe
R or ESVI 45 ml/m2) should be carefully
onitored for progression of AR or LV remodeling
33).
Patients 50 years incur minimal mortality.
hus, studies enrolling mostly young patients ob-
erved few deaths, and their suggestion that
ymptom-based decision-making is sufficient in AR
34) might be biased. In our series, cardiac events Mere similarly frequent with QASE-severe AR in
oung and older patients. Thus, QASE-severe AR
nd ESVI 45 ml/m2 should lead, even in younger
atients, to consideration of surgery.
tudy limitations. Our study was restricted to patients
ith preserved EF. Lack of association of EF with
utcome does not obviate prompt surgical consider-
tion in patients with low EF who are at high risk
3,5,6,20). The link between AR and atrial fibrillation
ight be disputed, but our data show that after
xclusion of patients with atrial fibrillation as the only
ardiac event, our results are unaffected and AR
uantitative grading and ESVI predict outcome. In
omparing outcome implications of quantitative and
et-based data, it is important to account for jet
irection and AR etiology. However, jet-width ratios
ere not different when stratified by QASE-grading
ccording to jet eccentricity (all p  0.31) or AR
tiology (all p  0.17). For prediction of outcome,
et-width ratio impact was not improved by focusing
n central jets, and individual variables such as pres-
ure half-time or aortic arch were not independently
redictive of outcome (all p  0.11), confirming the
uperior outcome predictive power of quantitative
ersus qualitative AR grading.
Loss of follow-up might bias the estimation of
utcome but was minimal in our study. Series
nalyzing outcome with data mining risk overfitting
35). Examining few prospectively predefined vari-
bles obviates overfitting, which is unlikely here.
Vasodilator treatment of AR is disputed (36,37)
nd inconsistently used, and we cannot draw con-
lusions regarding subsets in which vasodilators
ight be beneficial.
O N C L U S I O N S
he present prospective study shows that quantitative
chocardiography provides independent and superior
redictors of clinical outcome in AR and should be
outinely performed. Asymptomatic patients with EF
50% but QASE-severe AR (RVol 60 ml/beat or
RO30 mm2) and ESVI45 ml/m2 are at a high
isk of mortality and cardiac events. Cardiac surgery
or AR, which markedly reduces this risk, should be
arefully clinically considered.
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